SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-308051"
 

Search: onr:"swepub:oai:DiVA.org:uu-308051" > A population-based ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients

Abdulla, Maysaa (author)
Uppsala universitet,Klinisk och experimentell patologi,Rose-Marie Amini
Laszlo, Sofia (author)
Uppsala universitet,Klinisk och experimentell patologi
Triumf, Johanna (author)
Uppsala universitet,Experimentell och klinisk onkologi
show more...
Hedström, Gustaf (author)
Uppsala universitet,Experimentell och klinisk onkologi
Berglund, Mattias (author)
Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Karolinska Inst, Dept Biosci & Nutr, Novum, Huddinge, Sweden.
Enblad, Gunilla (author)
Uppsala universitet,Experimentell och klinisk onkologi
Amini, Rose-Marie (author)
Uppsala universitet,Klinisk och experimentell patologi,Rose-Marie Amini
show less...
 (creator_code:org_t)
2016
2016
English.
In: Acta Oncologica. - 0284-186X .- 1651-226X. ; 55:9-10, s. 1126-1131
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Aim: To determine the prognostic significance of co-expression of MYC, BCL-2 and BCL-6 proteins in combination with other biomarkers and clinical characteristics within a population-based cohort of diffuse large B-cell lymphoma (DLBCL) patients uniformly treated with R-CHOP.Patients and methods: The immunohistochemical (IHC) expression of CD10, BCL-2, BCL-6, MUM1, MYC, CD5, CD30, Ki-67 and p53 was evaluated in a retrospective, population-based study comprising 188 DLBCL patients treated with R-CHOP and diagnosed in Sweden between 2002 and 2012.Results: Patients had a median age at diagnosis of 64 years (26-85 years) with a male:female ratio of 1.4:1. Approximately half (52%) of the patients presented with an International Prognostic Index (IPI) age adjusted (IPIaa)2. Median follow-up time was 51 months (range 0.4-158) and the five-year lymphoma-specific survival (LSS) was 76%, five-year overall survival (OS) was 65% and five-year progression-free survival (PFS) was 61%. A high Ki-67 value was found in 59% of patients, while p53 overexpression was detected in 12% of patients and MYC, BCL-2 and BCL-6 expression were detected in 42%, 55% and 74% of patients, respectively. IPIaa2 (p=0.002), Ki-6770% (p=0.04) and p53 overexpression50% (p=0.02) were associated with inferior LSS and OS. Co-expression of both MYC (>40%) and BCL-2 (>70%) proteins was detected in 27% of patients and correlated with a significantly inferior LSS (p=0.0002), OS (p=0.009) and PFS (p=0.03). In addition, triple expression of MYC, BCL-2 and BCL-6, also correlated with a significantly inferior LSS (p=0.02).Conclusion: Concurrent expression of MYC and BCL-2 proteins, as detected by IHC, was strongly associated with an inferior survival in DLBCL patients treated with R-CHOP. Other markers affecting survival were triple expression of MYC, BCL-2 and BCL-6, IPIaa, high Ki-67 and p53 overexpression.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)

Keyword

Patologi
Pathology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view